发明名称 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS
摘要 The present invention is directed to novel nanomolar and picomolar inhibitors of HIV reverse transcriptase, pharmaceutical compositions therefrom and methods for inhibiting reverse transcriptase and treating HIV infections, especially included drug resistant strains of HIV-1 and HIV-2 and/or secondary disease states and/or conditions which occur as a consequence of HIV infection.
申请公布号 US2015105351(A1) 申请公布日期 2015.04.16
申请号 US201414509301 申请日期 2014.10.08
申请人 YALE UNIVERSITY 发明人 Jorgensen William L.;Anderson Karen S.
分类号 C07D471/04;C07D407/12;A61K45/06;C07D403/12;C07D239/54;A61K31/513 主分类号 C07D471/04
代理机构 代理人
主权项 1. A compound of the formula (I): wherein: R1 is H, a halogen (F, Cl, Br, I, especially F, Cl, or Br), CN, NO2, an optionally substituted alkyl group, preferably a C1-C6 alkyl group (preferably CH3 and including CF3); R3 is H, OH, a C1-C3 alkyl group which is optionally substituted with up to 3 halogens (preferably F), a halogen (preferably F, Cl or Br), NO2 or CN; Rp is an optionally substituted five- or six-membered heterocycle, including pyrimidine derivatives preferably linked at the 1-position of the pyrimidine, more often a uracil moiety linked at the 1-position which is optionally substituted at the 5- or 6-position (often the 5-position) with a substituent R2a; R2a is H, halogen (preferably F, Cl or Br), optionally substituted C1-C3 alkyl (preferably methyl, ethyl or trifluoromethyl), optionally substituted —O—(C1-C3) alkyl (methyl, ethyl, propyl, isopropyl), including O—CF3, CN; W is N or C; X1 isO or N—RX when W is C, andwhen W is N; Z is(the double bond can be on either side of the carbon depending on X1 and Y1); Y1 isO or N—RY when W is C, andwhen W is N; R2 is H, a C1-C6 alkyl (preferably C1-C3 alkyl, including cyclopropyl) or a C2-C6 alkenyl optionally substituted with up to three fluorines (e.g. CF3), CN or halogen (F, Br, Cl, I), C1-C6alkoxy; C1-C6 hydroxyalkyl, C1-C6 alkoxyalkyl, C1-C6 polyoxyalkyl (e.g., methoxyethoxy) or a vinyl-R2 (substituted on the first or second carbon of the vinyl group, preferably on the second carbon cis or trans, more preferably trans); and RX and RY are each independently H or a C1-C6 alkyl (or a C1-C3 alkyl) group, optionally substituted with one or two hydroxyl groups; m is 0, 1, 2, 3 or 4 and n is 0, 1, 2 or 3; and the pharmaceutically acceptable salts, solvates and polymorphs thereof; with the proviso that the following compounds are excluded: (1) the compound of formula I where Rp is uracil, W is C, X1 is N—RX, RX is H, Y1 iswhere R2 is H, R1 is 4-H, R3 is 6-H, Z iswhere R2 is H and m and n are 1; (2) the compound of formula I where Rp is uracil, W is N, X1 iswhere R2 is H, Y1 iswhere R2 is H, R1 is 4-H, R3 is 6-H, m and n are 1, Z isand R2 bound to the Z carbon is either CH3 or CN; (3) the compound of formula I where Rp is uracil, W is C, X1 is O, Y1 isR2 is H, Z ism and n are 1, R1 is 4-Cl, R3 is 6-H and R2 bound to the Z carbon is H or CH3; and (4) the compound of formula I where Rp is uracil, W is C, X1 iswhere R2 is H, Z iswhere R2 is H, Y1 is O, R1 is 4-Cl, R3 is 6-H and m and n are 1.
地址 NEW HAVEN CT US
您可能感兴趣的专利